ADMINISTRATIVE CORE Principal Investigator Matthew M. LaVail, Ph.D. is an internationally known senior vision scientist who has used many different types of research approaches, including anatomical, biochemical, classical genetic, molecular genetic and electrophysiological methods, as well as animal model development and neurotrophic factor and gene therapy studies for retinal degenerative diseases. His discoveries of circadian rod outer- segment disk shedding and the pharmaceutical rescue of degenerating photoreceptors have led to the establishment of new fields of vision research. He is highly respected at UCSF and in the vision research community. Dr. LaVail has been funded continuously by the NEI for the past 35 or more years with 6 different co-operative agreements, contracts and long-running research grants, so he is fully aware of both the research needs and regulations involved with NIH grants. Also, he has been an active member of the Core Grant Core Directors'Advisory Committee (see below), serving as the Imaging Core's first Director beginning in 1998. Through his leadership and effort in designing and constructing the Core, the Imaging Core has been the most heavily used of our Cores. Dr. LaVail distinguished himself, as well, in establishing procedures that would assure equitable access to the Core, even with very high usage at several times during the year just prior to several research meetings. One year before the retirement of the former Principal Investigator, Dr. Steven Kramer, Dr. LaVail was approved by the NE I to become the new Principal Investigator of the Core Grant effective July 1, 2002. We will use this process in case a Core Director or PI moves, retires or becomes unable to carry out the duties of the position, in which case the person will be identified by the Advisory Committee (see below), and the name will be submitted to the NEI for approval.

National Institute of Health (NIH)
National Eye Institute (NEI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZEY1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
LaVail, Matthew M; Yasumura, Douglas; Matthes, Michael T et al. (2016) Gene Therapy for MERTK-Associated Retinal Degenerations. Adv Exp Med Biol 854:487-93
Lamy, Ricardo; Chan, Elliot; Good, Samuel D et al. (2016) Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts. Clin Exp Ophthalmol 44:181-7
Rooney, Gemma E; Goodwin, Alice F; Depeille, Philippe et al. (2016) Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome. J Neurosci 36:142-52
Alavi, Marcel V; Mao, Mao; Pawlikowski, Bradley T et al. (2016) Col4a1 mutations cause progressive retinal neovascular defects and retinopathy. Sci Rep 6:18602
Flores, Alyssa M; Casey, Scott D; Felix, Christian M et al. (2016) Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease. FASEB J 30:1789-97
Ou, Yvonne; Jo, Rebecca E; Ullian, Erik M et al. (2016) Selective Vulnerability of Specific Retinal Ganglion Cell Types and Synapses after Transient Ocular Hypertension. J Neurosci 36:9240-52
Delwig, Anton; Larsen, DeLaine D; Yasumura, Douglas et al. (2016) Retinofugal Projections from Melanopsin-Expressing Retinal Ganglion Cells Revealed by Intraocular Injections of Cre-Dependent Virus. PLoS One 11:e0149501
Chou, Jonathan; Chan, Matilda F; Werb, Zena (2016) Metalloproteinases: a Functional Pathway for Myeloid Cells. Microbiol Spectr 4:
Della Santina, Luca; Ou, Yvonne (2016) Who's lost first? Susceptibility of retinal ganglion cell types in experimental glaucoma. Exp Eye Res :
McNamara, Nancy A; Ge, Shaokui; Lee, Salena M et al. (2016) Reduced Levels of Tear Lacritin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sjögren's Syndrome. Invest Ophthalmol Vis Sci 57:5237-5243

Showing the most recent 10 out of 453 publications